HCSG Healthcare Services (HCSG) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-nursing & personal care facilities · CIK 0000731012
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $0 priced
What the filings say about HCSG
Insiders, 180 days
-$362.5K net sold
1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$820.4K
2 notices
Healthcare Services insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, HEALTHCARE SERVICES GROUP INC insiders sold a net $362.5K of stock across 14 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 106.5% of the 17,125 shares held after it.
- No other insider sold within 30 days.
Insider activity: EVP/Gen. Counsel/Corp. Secty. Bundick Jason J sold about $458.0K of HCSG on Oct 26, 2026.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 68.6% of the 22,741 shares held after it.
- No other insider sold within 30 days.
Insider activity: EVP & Chief Operating Officer Kush Andrew sold about $362.5K of HCSG on Aug 4, 2026.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 26, 2025.
- The trade is 15.8% of the 15,735 shares held after it.
- 2 other insiders sold within 30 days.
Insider activity: SVP & Chief Accounting Officer Brophy Andrew M sold about $54.2K of HCSG on Feb 26, 2026; 2 other insiders sold within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 33.4% of the 33,448 shares held after it.
- 2 other insiders sold within 30 days.
Insider activity: EVP & Chief Revenue Officer Orr Patrick J sold about $229.5K of HCSG on Feb 18, 2026; 2 other insiders sold within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- 2 other insiders sold within 30 days.
Insider activity: EVP & Chief Revenue Officer Orr Patrick J sold about $686.4K of HCSG on Feb 18, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days.14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$362.5K over 180 days
-$362.5K over 90 days
more than 62% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+7.1% year over year
below 59% of Healthcare Services
Margin
3.2% net margin
more than 62% of Healthcare Services
Buybacks
$56.6M repurchased, FY to 2026-09-30
more than 52% of Healthcare Services
Short interest
4.0% of the float short (float per yahoo 2026-10-26) · 3.4 days to cover · settled 2026-09-30
more than 54% of Healthcare Services
What changed in the last 30 days
Oct 27EVP/Gen. Counsel/Corp. Secty. Bundick Jason J sold $458.0K (Oct 26)
Oct 26Officer JASON J BUNDICK filed to sell $457.9K by Oct 26 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch HCSG
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+35.0%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HCSG: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in HCSG
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HCSG planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
JASON J BUNDICK
Filed 2026-10-26
$457.9K
ANDREW KUSH
Filed 2026-08-04
$362.5K
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
IQVIA PHARMACY DATA · 2024-09-24
$20.9M
Department Of Health And Human Services
NATIONAL AND INTERNATIONAL PHARMACEUTICAL SALES DATA · 2022-09-28
$10.3M
Department Of Health And Human Services
SUBSCRIPTION ACCESS TO PRESCRIPTION DRUG DATA · 2023-09-30
$7.4M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · Theodore Wahl
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.7M
$12.2M
$1.4M
-26%
+55%
2024
$4.7M
$5.9M
$972.1K
-55%
+64%
2023
$4.6M
$3.3M
$1.1M
-60%
+44%
2022
$4.4M
$2.4M
$1.0M
-53%
+23%
2021
$4.4M
$1.4M
$986.0K
-35%
+42%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $362.5K sold by insiders over 180 days, $820.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
HCSG financials
Revenue growth
+7.1%
XBRL, annual
Net margin
3.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.9B
four quarters, 2025-10-01 to 2026-09-30
Revenue, TTM HCSG
| FY Dec 2025 | $1.8B |
| FY Dec 2024 | $1.7B |
| FY Dec 2023 | $1.7B |
| FY Dec 2022 | $1.7B |
| FY Dec 2021 | $1.6B |
| Sep 2026 | $479.6M |
| Jun 2026 | $470.8M |
| Mar 2026 | $462.8M |
| Dec 2025 | $466.7M |
| Sep 2025 | $464.3M |
| Jun 2025 | $458.5M |
| Mar 2025 | $447.7M |
| Dec 2024 | $437.8M |
At each fiscal year end
Single quarter
Net margin, TTM
+5.6%
net income over revenue, 2025-10-01 to 2026-09-30
Net margin, TTM HCSG
| FY Dec 2025 | +3.2% |
| FY Dec 2024 | +2.3% |
| FY Dec 2023 | +2.3% |
| FY Dec 2022 | +2.0% |
| FY Dec 2021 | +3.0% |
| Sep 2026 | +5.2% |
| Jun 2026 | +4.8% |
| Mar 2026 | +5.6% |
| Dec 2025 | +6.7% |
| Sep 2025 | +9.3% |
| Jun 2025 | -7.1% |
| Mar 2025 | +3.8% |
| Dec 2024 | +2.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$106.7M
operating cash flow minus capex, 2025-10-01 to 2026-09-30
Free cash flow, TTM HCSG
| FY Dec 2025 | $139.2M |
| FY Dec 2024 | $24.5M |
| FY Dec 2023 | $38.1M |
| FY Dec 2022 | -$13.4M |
| FY Dec 2021 | $31.4M |
| Sep 2026 | $28.1M |
| Jun 2026 | $20.2M |
| Mar 2026 | $42.3M |
| Dec 2025 | $16.0M |
| Sep 2025 | $70.0M |
| Jun 2025 | $27.4M |
| Mar 2025 | $25.8M |
| Dec 2024 | $34.8M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity HCSG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt HCSG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+20.4%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on equity HCSG
| FY Dec 2025 | +11.7% |
| FY Dec 2024 | +8.3% |
| FY Dec 2023 | +8.8% |
| FY Dec 2022 | +7.9% |
| FY Dec 2021 | +10.6% |
| Sep 2026 | +20.4% |
| Jun 2026 | +24.7% |
| Mar 2026 | +13.2% |
| Dec 2025 | +11.7% |
| Sep 2025 | +8.1% |
| Jun 2025 | +2.3% |
| Mar 2025 | +8.4% |
| Dec 2024 | +8.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+12.7%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on assets HCSG
| FY Dec 2025 | +7.4% |
| FY Dec 2024 | +5.0% |
| FY Dec 2023 | +5.1% |
| FY Dec 2022 | +4.6% |
| FY Dec 2021 | +6.2% |
| Sep 2026 | +12.7% |
| Jun 2026 | +15.2% |
| Mar 2026 | +8.3% |
| Dec 2025 | +7.4% |
| Sep 2025 | +4.9% |
| Jun 2025 | +1.3% |
| Mar 2025 | +5.1% |
| Dec 2024 | +5.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital HCSG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed HCSG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
16.97x
close 2026-10-26 over four quarters of diluted EPS, 2025-10-01 to 2026-09-30
P/E, trailing HCSG
| FY Dec 2025 | 23.60x |
| FY Dec 2024 | 21.52x |
| FY Dec 2023 | 19.94x |
| FY Dec 2022 | 26.67x |
| FY Dec 2021 | 26.95x |
| Sep 2026 | 13.82x |
| Jun 2026 | 14.36x |
| Mar 2026 | 19.53x |
| Dec 2025 | 23.60x |
| Sep 2025 | 31.17x |
| Jun 2025 | 107.36x |
| Mar 2025 | 18.00x |
| Dec 2024 | 21.52x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value HCSG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield HCSG
| FY Dec 2025 | +10.3% |
| FY Dec 2024 | +2.9% |
| FY Dec 2023 | +5.0% |
| FY Dec 2022 | -1.5% |
| FY Dec 2021 | +2.4% |
| Sep 2026 | +7.6% |
| Jun 2026 | +8.8% |
| Mar 2026 | +11.9% |
| Dec 2025 | +10.3% |
| Sep 2025 | +13.0% |
| Jun 2025 | +8.3% |
| Mar 2025 | +10.6% |
| Dec 2024 | +2.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.10x
P/E over trailing EPS growth of 174%: four quarters to 2026-09-30 against the four to 2025-09-30
PEG, trailing HCSG
| FY Dec 2025 | 0.47x |
| FY Dec 2024 | 5.59x |
| FY Dec 2023 | 1.28x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Sep 2026 | 0.08x |
| Jun 2026 | 0.01x |
| Mar 2026 | 0.28x |
| Dec 2025 | 0.47x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 5.59x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.8B | $1.7B | $1.7B | $1.7B |
| Net income | $59.1M | $39.5M | $38.4M | $34.2M |
| EPS (diluted) | 0.81 | 0.53 | 0.52 | 0.46 |
| Operating cash flow | $145.0M | $30.8M | $43.5M | -$8.2M |
| Cash | $125.2M | $56.8M | $54.3M | $26.3M |
| Buybacks | $61.6M | $5.0M | $11.3M | $0 |
| Dividends paid | n/a | $0 | $0 | $63.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
HCSG Stock Sonar score 4/7 axes
Find similar shapesCompareHCSG ranks highest on profitability (89th percentile) and risk and compliance (39th), and lowest on growth (21st), among Healthcare Services peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HCSG filings, in plain words
Are Healthcare Services insiders buying or selling HCSG?
In the 180 days to 2026-10-28, Healthcare Services insiders were net sellers, a net $362.5K across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of HCSG?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $820.4K of stock; the latest, by JASON J BUNDICK, was filed 2026-10-26.
Read the full summary
In the 180 days to 2026-10-28, Healthcare Services insiders were net sellers of HCSG, a net $362.5K across purchases and sales reported on Form 4 by 1 seller. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $820.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
